Literature DB >> 21725709

A fast method for testing covariates in population PK/PD Models.

Akash Khandelwal1, Kajsa Harling, E Niclas Jonsson, Andrew C Hooker, Mats O Karlsson.   

Abstract

The development of covariate models within the population modeling program like NONMEM is generally a time-consuming and non-trivial task. In this study, a fast procedure to approximate the change in objective function values of covariate-parameter models is presented and evaluated. The proposed method is a first-order conditional estimation (FOCE)-based linear approximation of the influence of covariates on the model predictions. Simulated and real datasets were used to compare this method with the conventional nonlinear mixed effect model using both first-order (FO) and FOCE approximations. The methods were mainly assessed in terms of difference in objective function values (ΔOFV) between base and covariate models. The FOCE linearization was superior to the FO linearization and showed a high degree of concordance with corresponding nonlinear models in ΔOFV. The linear and nonlinear FOCE models provided similar coefficient estimates and identified the same covariate-parameter relations as statistically significant or non-significant for the real and simulated datasets. The time required to fit tesaglitazar and docetaxel datasets with 4 and 15 parameter-covariate relations using the linearization method was 5.1 and 0.5 min compared with 152 and 34 h, respectively, with the nonlinear models. The FOCE linearization method allows for a fast estimation of covariate-parameter relations models with good concordance with the nonlinear models. This allows a more efficient model building and may allow the utilization of model building techniques that would otherwise be too time-consuming.

Entities:  

Mesh:

Year:  2011        PMID: 21725709      PMCID: PMC3160160          DOI: 10.1208/s12248-011-9289-2

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  15 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

3.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

4.  The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.

Authors:  Karin Tunblad; Lars Lindbom; Lynn McFadyen; E Niclas Jonsson; Scott Marshall; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-15       Impact factor: 2.745

5.  Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

Authors:  M O Karlsson; E N Jonsson; C G Wiltse; J R Wade
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

6.  Automated covariate model building within NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

7.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

8.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Authors:  R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

9.  Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.

Authors:  Charlotte Kloft; Johan Wallin; Anja Henningsson; Etienne Chatelut; Mats O Karlsson
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

10.  Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment.

Authors:  B Hamrén; E Björk; M Sunzel; Mo Karlsson
Journal:  Clin Pharmacol Ther       Date:  2008-03-19       Impact factor: 6.875

View more
  20 in total

Review 1.  Covariate selection in pharmacometric analyses: a review of methods.

Authors:  Matthew M Hutmacher; Kenneth G Kowalski
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  Concordance between criteria for covariate model building.

Authors:  Stefanie Hennig; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-06       Impact factor: 2.745

3.  Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.

Authors:  Chiara Piana; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

4.  Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.

Authors:  Mats O Magnusson; Mahesh N Samtani; Elodie L Plan; E Niclas Jonsson; Stefaan Rossenu; An Vermeulen; Alberto Russu
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

5.  A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.

Authors:  Wynand Smythe; Akash Khandelwal; Corinne Merle; Roxana Rustomjee; Martin Gninafon; Mame Bocar Lo; Oumou Bah Sow; Piero L Olliaro; Christian Lienhardt; John Horton; Peter Smith; Helen McIlleron; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

6.  Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.

Authors:  Maxwell T Chirehwa; Richard Court; Mariana de Kock; Lubbe Wiesner; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Rob Warren; Paolo Denti; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.

Authors:  Aksana K Jones; Eliford Ngaimisi; Mathangi Gopalakrishnan; Malcolm A Young; Celine M Laffont
Journal:  Clin Pharmacokinet       Date:  2020-11-02       Impact factor: 6.447

8.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.

Authors:  R J Keizer; M O Karlsson; A Hooker
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-26

9.  Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.

Authors:  W Huisinga; A Solms; L Fronton; S Pilari
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

10.  A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment.

Authors:  J-S van der Walt; Y Hong; L Zhang; M Pfister; D W Boulton; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.